PDF(Pubmed)
Abstract：
UNASSIGNED: Lung cancer is the leading cause of cancer death worldwide and the majority of the patients have advanced/metastatic disease on presentation. In clinical practice, several biomarkers and clinical factors are taken into account when choosing the best treatment option in advanced non-small-cell lung cancer (NSCLC). One potential marker may be tumor burden (TB). However, this concept is not specifically defined in NSCLC, and usually, it is used as a synonymous for aggressive disease.
UNASSIGNED: A non-systematic literature review was conducted. We searched for eligible randomized controlled trials from PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials with a cutoff at February 2021. The keywords included non-small-cell lung cancer, tumor burden, aggressive disease, prognosis biomarker, predictive biomarker, and immunotherapy.
UNASSIGNED: This review addresses the definition of TB in advanced NSCLC, the pathophysiology of high TB lesions, and the role of TB as a prognosis biomarker.
UNASSIGNED: The concept of aggressive disease, as high tumor burden definition, remains poorly defined and rarely considered in clinical research or clinical practice in oncology. The identification of this subgroup of patients could be interesting for defining and optimizing a more aggressive treatment strategy.
UNASSIGNED: A non-systematic literature review was conducted. We searched for eligible randomized controlled trials from PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials with a cutoff at February 2021. The keywords included non-small-cell lung cancer, tumor burden, aggressive disease, prognosis biomarker, predictive biomarker, and immunotherapy.
UNASSIGNED: This review addresses the definition of TB in advanced NSCLC, the pathophysiology of high TB lesions, and the role of TB as a prognosis biomarker.
UNASSIGNED: The concept of aggressive disease, as high tumor burden definition, remains poorly defined and rarely considered in clinical research or clinical practice in oncology. The identification of this subgroup of patients could be interesting for defining and optimizing a more aggressive treatment strategy.
摘要：
未经证实：肺癌是全球癌症死亡的主要原因，大多数患者在出现时患有晚期/转移性疾病。在临床实践中,在选择晚期非小细胞肺癌(NSCLC)的最佳治疗方案时,我们考虑了几种生物标志物和临床因素.一种潜在的标志物可能是肿瘤负荷(TB)。然而,这个概念在非小细胞肺癌中没有特别定义，通常,它被用作侵袭性疾病的同义词。
UNASSIGNED：进行了非系统文献综述。我们从PubMed搜索了符合条件的随机对照试验，EMBASE,和Cochrane中央受控试验登记册，截止日期为2021年2月。关键词包括非小细胞肺癌，肿瘤负荷，侵袭性疾病,预后生物标志物，预测性生物标志物，和免疫疗法。
未经评估：这篇综述讨论了晚期非小细胞肺癌中结核病的定义，高结核病病变的病理生理学，以及结核病作为预后生物标志物的作用。
未经批准：侵袭性疾病的概念，作为高肿瘤负荷定义，仍然不明确，很少在临床研究或肿瘤学临床实践中考虑。该患者亚组的识别对于定义和优化更积极的治疗策略可能是有趣的。
UNASSIGNED：进行了非系统文献综述。我们从PubMed搜索了符合条件的随机对照试验，EMBASE,和Cochrane中央受控试验登记册，截止日期为2021年2月。关键词包括非小细胞肺癌，肿瘤负荷，侵袭性疾病,预后生物标志物，预测性生物标志物，和免疫疗法。
未经评估：这篇综述讨论了晚期非小细胞肺癌中结核病的定义，高结核病病变的病理生理学，以及结核病作为预后生物标志物的作用。
未经批准：侵袭性疾病的概念，作为高肿瘤负荷定义，仍然不明确，很少在临床研究或肿瘤学临床实践中考虑。该患者亚组的识别对于定义和优化更积极的治疗策略可能是有趣的。
